Skip to Content

Stem cell startup Magenta Therapeutics is developing quickly, thanks in part to a clinical trial agreement with the U's Bone Marrow Transplantation Program. 

Magenta Therapeutics Inc. of Cambridge filed IPO registration documents with the U.S. Securities Exchange Commission just before the long Memorial Day weekend, revealing its intention to go public just weeks after raising $50 million in a Series C venture capital financing round.

Read the full story in Twin Cities Business.